Provided by Tiger Trade Technology Pte. Ltd.

ENGENE HOLDINGS INC

1.94
-0.0400-2.02%
Post-market: 1.91-0.0300-1.55%19:30 EDT
Volume:692.75K
Turnover:1.38M
Market Cap:129.95M
PE:-0.96
High:2.02
Open:2.00
Low:1.93
Close:1.98
52wk High:12.25
52wk Low:1.40
Shares:66.98M
Float Shares:32.73M
Volume Ratio:0.71
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0205
EPS(LYR):-2.2947
ROE:-60.50%
ROA:-31.99%
PB:0.56
PE(LYR):-0.85

Loading ...

enGene downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
May 08

enGene Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $4 From $7

THOMSON REUTERS
·
May 08

enGene downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
May 08

enGene announces updated interim results from LEGEND cohort

TIPRANKS
·
May 07

EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint

Dow Jones
·
May 07

enGene reports 43% six-month complete response in Phase 2 LEGEND bladder cancer trial

Reuters
·
May 07

enGene Therapeutics Inc - Detaimigene Achieves 54% Complete Response at Any Time, 43% at Six Months as of April 21, 2026

THOMSON REUTERS
·
May 07

enGene Therapeutics Inc - 2.4% Experienced Treatment Interruption, 2.4% Discontinuation Due to Adverse Events

THOMSON REUTERS
·
May 07

enGene Therapeutics Inc - 55% Experienced Treatment-Related Adverse Events of Detalimogene, Mostly Mild

THOMSON REUTERS
·
May 07

H.C. Wainwright Keeps Their Buy Rating on enGene Holdings (ENGN)

TIPRANKS
·
Apr 29

enGene Holdings Initiated at Buy by WBB Securities

Dow Jones
·
Apr 14

enGene Holdings changes name to enGene Therapeutics as it eyes 2027 launch

Reuters
·
Apr 10

BRIEF-Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026

Reuters
·
Apr 07

enGene Holdings Inc - Planned Bla Submission for Detalimogene in Second Half of 2026

THOMSON REUTERS
·
Apr 07

enGene Holdings Inc - to Change Name to enGene Therapeutics Inc. Effective April 8, 2026

THOMSON REUTERS
·
Apr 07

enGene Holdings changes name to enGene Therapeutics effective April 8, 2026

Reuters
·
Apr 07

Three new option listings and three option delistings on April 6th

TIPRANKS
·
Apr 06